About
Sera Medicines is a biologics-focused accelerator advancing next-generation protein therapeutics to treat complex diseases with significant unmet medical needs.
Our team consists of experts in biology, chemistry, antibody engineering, drug discovery, manufacturing, clinical development, operations, and business development, who combine their talents to create and launch exceptional companies.
Once a program incubated at Sera achieves key value inflection, we enable rapid progression toward and beyond the clinic via the formation and financing of spinouts, such as Tenet Medicines and Navigator Medicines.
Meet The Team
News
Navigator Medicines Announces $100 Million Series A Financing and In-Licensing of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
Our Investors
RA Capital Management has been a primary investor in Sera Medicines since its founding in 2023. The firm invests in healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools.
RA Capital’s portfolio of private and public companies spans the globe and covers all stages from discovery through commercialization. RA Capital is partnering with Sera Medicines to invest in promising new biologics-focused therapies and works closely with the Sera team to research new ideas and drive value creation.
